Lukas Scheibler - Apr 21, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
CHIEF INNOVATION OFFICER
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol
APLS
Transactions as of
Apr 21, 2022
Transactions value $
-$430,000
Form type
4
Date filed
5/31/2022, 04:30 PM
Previous filing
Apr 6, 2022
Next filing
Jan 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -1.88K -3.59% $0.00 50.4K Apr 21, 2022 Direct F1
transaction APLS Common Stock Sale -$430K -10K -19.86% $43.00 40.4K May 27, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Other $0 -11.3K -100% $0.00* 0 Apr 21, 2022 Common Stock 11.3K $44.90 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This is a scheduled sale from 10B5-1 trading plan.
F3 This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
F4 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.